Coeptis Therapeutics (COEP) VP gets stock grant, exercises options

Rhea-AI Filing Summary

Coeptis Therapeutics Holdings, Inc. officer Christine Elise Sheehy, VP Compliance and Secretary, increased her direct holdings of common stock through compensation-related transactions. On February 11, 2026, she exercised stock options to acquire 1,000 shares of common stock at an exercise price of $10.56 per share, reflecting the cost to convert her options into shares.

On the same date, she also acquired 12,500 shares of restricted common stock at $0 per share as part of an option exchange program in which underwater options were surrendered for restricted stock. After these transactions, she directly beneficially owned 64,031 shares of Coeptis common stock.

Insights

Equity compensation analyst

Officer increases equity stake via option exercise and restricted stock grant.

Christine Elise Sheehy, VP Compliance and Secretary of Coeptis Therapeutics Holdings, acquired common stock through an option exercise and an option-exchange-related restricted stock grant. The filing shows compensation-related equity activity rather than open-market buying or selling.

The 1,000-share acquisition at an exercise price of $10.56 came from exercising stock options. The additional 12,500 restricted shares were granted at $0 per share in exchange for surrendering underwater options, shifting value from options to full-value stock awards.

Following these transactions on February 11, 2026, Sheehy directly beneficially owned 64,031 shares of common stock. Future company filings may further detail the vesting or restrictions on the newly granted restricted stock and any subsequent changes in her ownership position.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sheehy Christine Elise

(Last) (First) (Middle)

105 BRADFORD RD, SUITE 420

(Street)

WEXFORD PA 15090

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coeptis Therapeutics Holdings, Inc. [ COEP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP Compliance and Secy

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	02/11/2026		M		1,000	A	$10.56(1)	64,031	D
Common Stock	02/11/2026		A		12,500	A	$0(2)	64,031	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the exercise price of shares purchased upon exercise of stock options.

2. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

	/s/ Christine E. Sheehy	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did COEP VP Christine Sheehy report on this Form 4?

She reported two acquisitions of Coeptis common stock. She exercised stock options for 1,000 shares at $10.56 per share and received a separate grant of 12,500 restricted shares at $0 per share through an option exchange program.

Did the COEP insider buy shares on the open market in this filing?

No, the transactions were compensation-related. One came from exercising stock options for 1,000 shares at a $10.56 exercise price, and the other was a 12,500-share restricted stock grant issued via an option exchange of underwater options.

How many Coeptis Therapeutics (COEP) shares does Christine Sheehy own after these transactions?

After the reported transactions, Christine Elise Sheehy directly beneficially owned 64,031 shares of Coeptis Therapeutics common stock. This total reflects both the 1,000 shares from the option exercise and the 12,500 restricted shares granted in the option exchange program.

What is the significance of the $10.56 price in the COEP Form 4?

The $10.56 figure is the exercise price for stock options converted into 1,000 shares of Coeptis common stock. It represents the per-share cost Sheehy paid to exercise her options, not a market purchase price on an exchange.

What does the 12,500-share restricted stock grant mean for COEP’s VP?

The 12,500 restricted shares were granted at $0 per share in an option exchange program. Sheehy surrendered underwater stock options and received restricted stock instead, increasing her direct share ownership while shifting her compensation mix from options to full-value shares.

Is Christine Sheehy a director or major shareholder of Coeptis Therapeutics (COEP)?

In this filing, Sheehy is identified as an officer, serving as VP Compliance and Secretary, but not as a director or 10% owner. The Form 4 reflects her status as a reporting officer under Section 16 of U.S. securities laws.